STRONG SELL/ 50% downside potential, page-27

wombat, have a look at PAR. They stumbled upon zilosul and repurposed the drug for OA.

Mesoblast purchased REM-L from Orisis and changed its design and techniques for administering etc as well.

ask CYDY whether fda accepted any of their IND results - they didn’t, and that meant hundreds of patients results were not included and not taken into account.

has the FDA said they will accept all results from the 1980s? What has their feedback been on accepting results 30 years after the fact. IMO the minute RAC changed anything to do with the drug, that means the board is regardless of time difference.

I think you are a very intelligent poster, and I believe RAC is one of the most exciting biotechs on ASX. But to say it is a unicorn is misleading, particularly when repurposing drugs is not a new thing.

moreso, I get the point about potential buyouts after phase 2. But they are the exception, not the rule - and that rule would state to get a P2 trial finished and successful in the US takes many many years.